Aliskiren	angiotensinogen	9	9	true	positive	Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		325646	none	325646	none
Aliskiren	angiotensinogen	9	9	true	positive	Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		325646	none	325646	none
Aliskiren	aliskiren	16	16	false	none	12.3 Pharmacokinetics    Aliskiren is poorly absorbed (bioavailability about 2.5%) with an approximate accumulation half life of 24 hours.  		325646	C446481
Aliskiren	aliskiren	16	18	false	none	12.3 Pharmacokinetics    Aliskiren is poorly absorbed (bioavailability about 2.5%) with an approximate accumulation half life of 24 hours.  Steady state blood levels are reached in about 7-8 days.  Absorption and Distribution    Following oral administration, peak plasma concentrations of aliskiren are reached within 1 – 3 hours.  		325646	C446481
Aliskiren	aliskiren	19	19	true	positive	When taken with a high fat meal, mean AUC and Cmax of aliskiren are decreased by 71% and 85% respectively.  		325646	C446481
Aliskiren	aliskiren	19	18	true	positive	Absorption and Distribution    Following oral administration, peak plasma concentrations of aliskiren are reached within 1 – 3 hours.  When taken with a high fat meal, mean AUC and Cmax of aliskiren are decreased by 71% and 85% respectively.  		325646	C446481
Aliskiren	aliskiren	19	20	true	positive	When taken with a high fat meal, mean AUC and Cmax of aliskiren are decreased by 71% and 85% respectively.  In the clinical trials of aliskiren, it was administered without requiring a fixed relation of administration to meals.  		325646	C446481
Aliskiren	aliskiren	18	16	false	none	12.3 Pharmacokinetics    Aliskiren is poorly absorbed (bioavailability about 2.5%) with an approximate accumulation half life of 24 hours.  Steady state blood levels are reached in about 7-8 days.  Absorption and Distribution    Following oral administration, peak plasma concentrations of aliskiren are reached within 1 – 3 hours.  		325646	C446481
Aliskiren	aliskiren	18	19	true	positive	Absorption and Distribution    Following oral administration, peak plasma concentrations of aliskiren are reached within 1 – 3 hours.  When taken with a high fat meal, mean AUC and Cmax of aliskiren are decreased by 71% and 85% respectively.  		325646	C446481
Aliskiren	aliskiren	18	18	false	none	Absorption and Distribution    Following oral administration, peak plasma concentrations of aliskiren are reached within 1 – 3 hours.  		325646	C446481
Aliskiren	aliskiren	18	20	true	positive	Absorption and Distribution    Following oral administration, peak plasma concentrations of aliskiren are reached within 1 – 3 hours.  When taken with a high fat meal, mean AUC and Cmax of aliskiren are decreased by 71% and 85% respectively.  In the clinical trials of aliskiren, it was administered without requiring a fixed relation of administration to meals.  		325646	C446481
Aliskiren	aliskiren	20	19	true	positive	When taken with a high fat meal, mean AUC and Cmax of aliskiren are decreased by 71% and 85% respectively.  In the clinical trials of aliskiren, it was administered without requiring a fixed relation of administration to meals.  		325646	C446481
Aliskiren	aliskiren	20	18	true	positive	Absorption and Distribution    Following oral administration, peak plasma concentrations of aliskiren are reached within 1 – 3 hours.  When taken with a high fat meal, mean AUC and Cmax of aliskiren are decreased by 71% and 85% respectively.  In the clinical trials of aliskiren, it was administered without requiring a fixed relation of administration to meals.  		325646	C446481
Aliskiren	aliskiren	20	20	false	none	In the clinical trials of aliskiren, it was administered without requiring a fixed relation of administration to meals.  		325646	C446481
Aliskiren	aliskiren	23	23	false	none	Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP3A4.  		325646	C446481
Aliskiren	aliskiren	23	25	false	none	Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP3A4.  Renally Impaired Patients: Aliskiren was evaluated in patients with varying degrees of renal insufficiency.  The rate and extent of exposure (AUC and Cmax) of aliskiren in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment.  		325646	C446481
Aliskiren	aliskiren	23	24	false	none	Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP3A4.  Renally Impaired Patients: Aliskiren was evaluated in patients with varying degrees of renal insufficiency.  		325646	C446481
Aliskiren	aliskiren	25	23	false	none	Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP3A4.  Renally Impaired Patients: Aliskiren was evaluated in patients with varying degrees of renal insufficiency.  The rate and extent of exposure (AUC and Cmax) of aliskiren in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment.  		325646	C446481
Aliskiren	aliskiren	25	25	false	none	The rate and extent of exposure (AUC and Cmax) of aliskiren in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment.  		325646	C446481
Aliskiren	aliskiren	25	24	false	none	Renally Impaired Patients: Aliskiren was evaluated in patients with varying degrees of renal insufficiency.  The rate and extent of exposure (AUC and Cmax) of aliskiren in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment.  		325646	C446481
Aliskiren	aliskiren	25	27	false	none	The rate and extent of exposure (AUC and Cmax) of aliskiren in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment.  Adjustment of the starting dose is not required in these patients [See Dosage and Administration (2.4 )].  Hepatically Impaired Patients: The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver disease.  		325646	C446481
Aliskiren	aliskiren	24	23	false	none	Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP3A4.  Renally Impaired Patients: Aliskiren was evaluated in patients with varying degrees of renal insufficiency.  		325646	C446481
Aliskiren	aliskiren	24	25	false	none	Renally Impaired Patients: Aliskiren was evaluated in patients with varying degrees of renal insufficiency.  The rate and extent of exposure (AUC and Cmax) of aliskiren in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment.  		325646	C446481
Aliskiren	aliskiren	24	24	false	none	Renally Impaired Patients: Aliskiren was evaluated in patients with varying degrees of renal insufficiency.  		325646	C446481
Aliskiren	aliskiren	9	9	true	positive	Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		325646	C446481
Aliskiren	aliskiren	27	25	false	none	The rate and extent of exposure (AUC and Cmax) of aliskiren in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment.  Adjustment of the starting dose is not required in these patients [See Dosage and Administration (2.4 )].  Hepatically Impaired Patients: The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver disease.  		325646	C446481
Aliskiren	aliskiren	27	27	false	none	Hepatically Impaired Patients: The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver disease.  		325646	C446481
Aliskiren	aliskiren	27	29	false	none	Hepatically Impaired Patients: The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver disease.  Consequently, adjustment of the starting dose is not required in these patients [See Dosage and Administration (2.4 )].  Pediatric Patients: The pharmacokinetics of aliskiren have not been investigated in patients <18years of age [See Dosage and Administration (2.4)].  		325646	C446481
Aliskiren	aliskiren	29	27	false	none	Hepatically Impaired Patients: The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver disease.  Consequently, adjustment of the starting dose is not required in these patients [See Dosage and Administration (2.4 )].  Pediatric Patients: The pharmacokinetics of aliskiren have not been investigated in patients <18years of age [See Dosage and Administration (2.4)].  		325646	C446481
Aliskiren	aliskiren	29	29	false	none	Pediatric Patients: The pharmacokinetics of aliskiren have not been investigated in patients <18years of age [See Dosage and Administration (2.4)].  		325646	C446481
Aliskiren	aliskiren	12	12	false	none	During treatment with aliskiren, however, the effect of increased renin levels is blocked so that PRA, Ang I and Ang II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.  		325646	C446481
Aliskiren	aldosterone	9	8	false	none	This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS).  Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		325646	1312358	325646	1312358
Aliskiren	aldosterone	9	8	false	none	This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS).  Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		325646	1312358	325646	1312358
angiotensinogen	aliskiren	9	9	true	positive	Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		none	325646	none	C446481
angiotensinogen	aliskiren	9	9	true	positive	Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		none	325646	none	C446481
angiotensinogen	aldosterone	9	8	false	none	This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS).  Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		none	1312358	none	1312358
angiotensinogen	aldosterone	9	8	false	none	This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS).  Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		none	1312358	none	1312358
aliskiren	aldosterone	9	8	false	none	This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS).  Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		325646	1312358	C446481	1312358
aliskiren	aldosterone	9	8	false	none	This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS).  Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.  		325646	1312358	C446481	1312358
